Dr. Roy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4500 San Pablo Road S
Jacksonville, FL 32224
Summary
- Dr. Vivek Roy is a hematology specialist based in Mayo Clinic in Jacksonville, FL where he also serves as Professor of Medicine. He has extensive training and experience in areas like multiple myeloma, amyloidosis, stem cell transplantation and cellular therapies such as CAR-T. He completed his residency in Internal Medicine at UMass Chan Medical School, followed by a fellowship in Hematology and Medical Oncology at the University of Minnesota. Dr. Roy's research focuses on multiple myeloma and hematopoietic stem cell transplantation, and he holds numerous publications in prominent journals like NEJM, Transplantation and Cellular Therapy, Blood Cancer Journal and Leukemia. He is actively involved in clinical trials, serving as both a contact and principal investigator for studies on treatments for multiple myeloma.
Education & Training
- University of MinnesotaFellowship, Hematology and Medical Oncology, 1993 - 1996
- UMass Chan Medical SchoolResidency, Internal Medicine, 1991 - 1993
- All India Institute of Medical SciencesClass of 1980
Certifications & Licensure
- AZ State Medical License 2000 - Present
- FL State Medical License 2001 - 2027
- MN State Medical License 1994 - 2025
- OK State Medical License 1996 - 2005
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2002
Clinical Trials
- Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Start of enrollment: 2005 Aug 01
- ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer Start of enrollment: 2005 Aug 01
- Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Start of enrollment: 2003 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.Anmol Baranwal, Kimberly Langer, Vedavyas Gannamani, Danielle Rud, Alia Cibich
Blood Advances. 2025-03-14 - Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide.Anmol Baranwal, Kimberly J Langer, Mohamed A Kharfan-Dabaja, Ernesto Ayala, James Foran
Transplantation and Cellular Therapy. 2025-01-01 - 1 citationsPhase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.Ricardo D Parrondo, Betsy R LaPlant, Jamie Elliott, Andre Fernandez, Caitlin J Flott
Blood Cancer Journal. 2024-09-05
Journal Articles
- Targeting CD38 with Daratumumab Is Lethal to Waldenström Macroglobulinaemia CellsRichard Furman, Stephen M Ansell, Sikander Ailawadhi, Thomas E Witzig, Vivek Roy, Taimur Sher, Liuyan Jiang, British Journal of Haematology
- Utilization of Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Myeloma: A Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consen...John A Lust, Shaji K Kumar, Morie A Gertz, P Leif Bergsagel, Angela Dispenzieri, Francis K Buadi, Prashant Kapoor, Angela A Mayo, Wilson I Gonsalves, Rafael Fonseca, R..., Nature
Abstracts/Posters
- Phase I Study of a Novel Bcl-2 Inhibitor, at-101 in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)Vivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Trends in Early Mortality from Multiple Myeloma (MM): A Population-Based AnalysisVivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Sociodemographic and Clinical Characteristics Associated with PatientÍs Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on OutcomesVivek Roy, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
- Sharing Mayo Clinic: “Divine Design” Gives Multiple Myeloma Patient Transplant, Care at HomeSeptember 5th, 2021
- “Divine Design” Gives Multiple Myeloma Patient Transplant, Care at HomeSeptember 2nd, 2021
- NCCN Releases New Patient Guidelines on Anemia and NeutropeniaMay 3rd, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: